Sign in

    Samantha Schaeffer • Cantor Fitzgerald

    Samantha Schaeffer's questions to Alector Inc (ALEC) leadership

    Samantha Schaeffer's questions to Alector Inc (ALEC) leadership • Q2 2025

    Question

    Samantha Schaeffer of Cantor Fitzgerald asked if the company expects to see signs of disease progression or a treatment effect in the 16 asymptomatic patients enrolled in INFRONT3 within the 96-week trial period. She also inquired about the patient rollover rate into the open-label extension study.

    Answer

    CMO Giacomo Salvadore noted that the asymptomatic cohort is part of a sensitivity analysis and could not comment on expected outcomes as the trial is blinded. CEO Arnon Rosenthal added these patients were selected based on high neurofilament levels, which suggests a risk of conversion. Regarding the open-label extension, Giacomo Salvadore said the company is satisfied with the rollover rate but has not disclosed specific numbers.

    Ask Fintool Equity Research AI

    Samantha Schaeffer's questions to Arcturus Therapeutics Holdings Inc (ARCT) leadership

    Samantha Schaeffer's questions to Arcturus Therapeutics Holdings Inc (ARCT) leadership • Q1 2025

    Question

    Samantha Schaeffer, on for Pete Stavropoulos at Cantor Fitzgerald, asked about the potential for ARCT-032 to remodel or normalize the lungs over time and what other measurements beyond FEV, such as quality of life, are being used to build conviction.

    Answer

    President and CEO Joseph Payne expressed optimism that ARCT-032 could lead to lung regeneration over time, as the topically administered agent could allow for steady improvement as the lung heals. He confirmed that in addition to FEV, a validated CF quality of life questionnaire is being used to complement the primary endpoint data, although the FDA has indicated FEV improvement is sufficient to advance the program.

    Ask Fintool Equity Research AI